Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wonder if Scott even owns a big position here? Something tells me he does not.
Yeah 10.5 miln shares with a previous avg of 174,000, i think you have to deduct, a fund or funds , having full knowledge where this is going, is knocking at the door.
If you have been into ATOS SINCE THE initial Private Placement , and through the $5 IPO in 2012 , you know that "we aint seen nuttin yet".
In '12/13 this co rocketed up to $13, then when quesitons came in from the FDA about certain claims that were "supposedly made" the co took it's Foresite product off the market voluntarily. Then for at least one year they made due with with the preliminary FDA approval process, after which they got another round of questions, and finally were turned down for their Foresite product, one of 5 products. They did however have approval for their next generation product Fullcyte, and although it is not as accurate as the Forecyte product, it is far and away more accurate than the next level of competition, which by the way, has a valuation in the 100's of millions (i recall $300 mln) . And by the way , Forcyte recently got it's European equivalent of FDA approval with a CE Mark in Europe.
So now you have the enviable position of a launch over seas. Their secont product Fullcyte just launched here in the States , and the pharmacogenetics also just recently launched.
Did i mention there are two more applications? You even have one application that addresses very early stage CA in the breast ducts .
Be that as it may, the reason i have remained in the opportunity since 2011 and stockpiled is for the perseverance , resiliance and genius of Steven Quay. He is technical genius , a marketing genius, and quant strategist.
This isnt going to stop at $5.5 as Zach's suggests , and now commercialized we will driven by accelerating revenue growth.
By the way , where did their huge patent portfolio come from? They purchase $1.4 billion in Paatent IP for a song, part from Roche and part from Sanofi Aventis, (if it wasnt Sanofi , it was a simlilar name recognized Pharma). They also have acquired Susan Day's IP!
And there are a lot more reasons than this, but this touches on some of the why's that convinced me to BE HERE.
Dream, they earlier had an announcement that for every two clinics they estimated they would do $3.6 mln in revs, what do you think about that number?
Big Yank , your saying that delaying the Plan is a Bad thing?
the 55 cents came less than two months ago and now 70 cents within the week.
I know two unsecured creditors who had been offered 55 cents on the dollar for their unsecured debt whom are now being offered 70 cents on the dollar, hmm, that is a good sign we could be the exception and not the norm,
Good idea/
Hey detearing i am hiring an atty to research the Pacer doc file for Xide, want to contact creditors to see if they have been offered 70% or more on their debt which brings the assurance that the debt will be totally covered , which means the shares should remain in tact. Do you know if anyone has researched this already?
Boy i made a mistake with General Growth too being out too soon, but this situation does not appear to be familiar to this situation. At the time General Growth was stuck in the rut that financing was scarce and chpt 11 was an alternative to convetional financing. I believe , Bill Achman? was in general Growth heavy at the time, i think he remained in , lucky dog.
I have a comml tenant that believes this co is going to recover very nicely and has big orders for ship batter casings, even got a big check today, he says they are getting out of the conventional batteries and specializing in big Commercial nad Military batteries.
But Why do you think that the co just wont cancel out our shares in favor of the bond holders?
How Exciting to be here on my surf board when a prodigous waive greets those invested for a unforgetable ride!
Excuse me GNBT did the seaside deal around the fall of 2011 not summer of 2012.
Seaside Partners, when management takes the path of least resistence , there is the price to pay. It was bound to happen , no question about it, Seaside has millions of shares to sell, what are they suppose to do with them?
Take a look at GNBT, they sold their shares to the Devil (Seaside) @ $.15 cents late summer 2012 and look how they are faring.
imagine the volume comming in when Ameritrade and WElls Fargo permits trading on this, i could only buy on my scottrade account , an account i seldom use.
I WILL TAKE 'EM ALL.
Wish i had seen this rebuttal friday morning , would'nt have had such an itchy trigger finger.
am i kirplimphed here? If Zaber had an interview with Globes ( the Israeli Bio Tech Paper) before the private placement, talking about the death of the 7 yr old girl and how they had no obligation to follow up when she left the hospital and then after the private plamcement said he did not know of the girls demise, was he not obligated to disclose this at the time of the Private Placement ? And could this not fall under an SEC investigation. Just asking.
This loan is real good, and loans do not come without a financial colonoscopy from the lender, in essense they are affirming the business model for NVIV.
What a great opportunity that would be!
stockpile between here and one . Opportunity knocks.. upside $30 / downside $1. they havent even started yet.
This is a stockpilers paradise.
If they have the license to the patent , is this a big deal?
PPM , the deal was $4.00 per share with 35% warrant coverage at $5.00 per share. This was not a dilutive offering. I put in for teh maximum shares of 20,000 (20,000 per customer) and only got 500 shares, so there you have it , this is a buying op, perhaps the last one.
likely scenario.
Friday should yield a chance to buy , bull.
missed purchasing on my $.625 bid on friday, and earlier in week at $.58 , too damn cautious .
i certainly agree with the scenario you have cast. By the way , you probably know this , that they had to send an abstract to the American Heart Association, and only after the abstract went in were they given the chance to speak, so it could only have been meritorious results , no other way. so we have a fate a compli event (spelling ?)
Meant whom is Honig? "Honig buying more shs on the 15th @ .74 " from your Aug 24th post.
Thnks Celtic, I have been on the product too for some time, I think I will walk over to the CVS next door and get a reading done.
Celt what kind of blood pressure reduction are your friends talking about, did they say?
This is a big story stock , what is a $.10 cent savings on a $3.00 move .10/3 = .033 who cares
executive churn is always a bad thing; and at this time remaining long is a "bet" that the resignation was just for non consequential reasons, brrrrrrrrr, just too risky a bet untile the smoke clears.
CONF CALL GOOD, SEAGAAP TEST (PLAVIC SCREENER) WILL BE IN 1000'S BY FIRST QTR NEXT YR, GOAL 1% OF TESTS 60,000 X $600 (EST) = $36,000,000 ACCRETIVE REVENEWS. THE WRITING IS ON THE WALLS HERE.
Celtics please explain the "Hanson Files had CDXC as experts"
By the way Wrinkles you are in the company of RT Kirk , Multi Billionaire Bio Tech stock picker , largest share holder, here.
IF YOU WANT I GET GET YOU THE CEOS CELL , CRAIG TUTTLE , HE IS A SWELL GUY .
just think , there are 6million plavic tests a year; only aruond60% that get plavic it works for . So everyone taking the test should have it screened to see if they should take Plavic or one of two other brands that would work that are not off patent.
Lets say , we capture 1000000 tests at $750 a test, that is $750,000,000 per year , This is possible , Craig Hallums price target of $3 could get nuked once traction is gained. Be in this one!
It's not you , scary market is right now . Sometimes though, it takes a while to get moving, especially for a small cap that esentially breaks even and no one follows.
But when they are doing , say 2000 tests a month at $750 a test (say six months) or $1,500,000 per month , it will get traction and Craig Hallum's forcast of $3 per share will look low.
The sales volume of this ingredient could be enormous.